Radiation pneumonitis is the main dose-limiting toxicity of thoracic radiotherapy, which can affect life quality, survival, and the tumor-controlling effects of patients receiving thoracic radiotherapy.
The purpose of this study is to:
* Identify biomarkers including serum proteins, gene expression, genetic changes, and epigenetic modifications that determine radiation pneumonitis. * Investigate the relationship between radiation pneumonitis and other toxicities induced by radiotherapy. * Construct a predictive model for radiation pneumonitis. * Evaluate survival and treatment outcome of patients with radiation pneumonitis.
Clinical diagnosis of lung cancer by histology
Radiation dose at least 45 Gy
Karnofsky >60
Age>18
Previous thoracic irradiation
Severe cardiopulmonary diseases
Lung cancer patients treated with thoracic radiotherapy.
Cohort
Prospective
Blood Samples for Biomarkers
Other interventionblood sample to be taken at baseline, during radiotherapy, and after radiotherapy
Radiation pneumonitis
radiation pneumonitis grade \>=2 or 3 graded by CTCAE4.0. \[Time Frame: 12 months after radiotherapy\]
Overall Survival
A long-term follow up will be scheduled to allow a complete survival analysis.
Other injuries induced by radiotherapy
Assessment of other common injuries induced by thoracic radiotherapy including injuries in heart, skin, and esophagus according to CTCAE4.0.
Click on the lead sponsor to view all of their trials.
Huazhong University of Science and Technology
Lead sponsor
Hubei Cancer Hospital
Collaborator
Jingjiang People' Hospital
Collaborator
